409A Valuations for Healthcare & Medtech Companies

How this page fits with our other guides: This article covers medical devices, diagnostics and health IT. Drug and therapeutics developers, whose value runs through clinical-phase success rates, are covered in our guide to 409A valuations for biotech startups. The mechanics of scenario analysis are in our PWERM guide. We link to those pages rather than repeat them here.

Why Medtech Is Not Biotech for a 409A

The rules do not change by industry. Treasury Regulations Section 1.409A-1(b)(5)(iv)(B)(1) requires a reasonable valuation method that considers the factors relevant to the business, including the value of its tangible and intangible assets, the present value of expected future cash flows, the market value of comparable companies, and recent arm's-length transactions in its stock. What changes for a healthcare company is which of those factors carries the evidence, and where the risk sits.

Healthcare startups are often grouped together, but a 409A valuation for a medtech company looks quite different from one for a drug developer:

• The regulatory path is shorter and pathway-specific. A drug typically passes through several phases of human trials over many years. Many devices reach the market through a premarket notification (510(k)) or a De Novo request, sometimes with limited or no new clinical data. Higher-risk devices need premarket approval, which is closer to a drug-style evidence burden.
• Iteration is normal. Devices improve in generations. A company may clear a first version quickly and then file for new indications or features, so value often builds in steps rather than in one approval.
• Reimbursement is a second gate. FDA clearance permits a device to be sold. It does not mean insurers will pay for it. Coverage, coding and payment can take as long as the regulatory work.
• Revenue arrives earlier. Device, diagnostics and health-IT companies often have revenue within a few years of founding, so comparable-company revenue multiples become usable sooner than in therapeutics.
• Manufacturing and sales are part of the risk. Quality systems, supply chains and the cost of building a sales force all affect how quickly a cleared product turns into cash.

For a side-by-side view of how software and drug-development companies differ, see our comparison of SaaS vs biotech 409A valuations. Medtech sits between the two.

How is a 409A valuation done for a medtech company?

A 409A valuation for a medtech company has three steps. The appraiser values the company, using its latest financing before clearance and revenue multiples from device or diagnostics peers once it sells product. That value is allocated across share classes, often with scenarios for regulatory and reimbursement outcomes. A discount for lack of marketability then gives the common stock's fair market value.

How much weight each source of evidence gets depends on the type of product and how far along it is. The table below shows how a healthcare startup 409A valuation typically shifts across the main segments.

For a fuller explanation of each approach and when it applies, see our guide to the income, market and cost approaches in a 409A.

How the FDA Pathway Shapes a Medical Device 409A Valuation

For a pre-revenue device company, the FDA pathway sets both the size of the remaining risk and how long the company must fund itself before it can sell. A medical device 409A valuation therefore starts with the regulatory plan:

• 510(k) premarket notification. The company shows its device is substantially equivalent to a legally marketed predicate device. When a good predicate exists, regulatory risk is usually modest. The appraiser asks whether the predicate fits and whether FDA may require clinical data.
• De Novo classification request. Used for novel low- to moderate-risk devices with no predicate. It carries more uncertainty than a 510(k), but a granted De Novo can become the predicate for later devices, including competitors'.
• Premarket approval (PMA). Required for most Class III devices, which support or sustain life or present a high risk. A PMA usually needs a pivotal clinical study, often run under an investigational device exemption, so timelines and cash needs look more like a clinical-stage company's.
• Breakthrough Devices Program. Designation brings more interaction with FDA and priority review. It does not change the standard a device must meet, so appraisers treat it as support for timing rather than as proof of success.

FDA's review goals range from 90 FDA days for a 510(k) to 180 days for a PMA, but elapsed time is usually longer once additional-information requests and holds are counted. Appraisers look for evidence that narrows the outcome: completed verification and validation testing, a pre-submission meeting and FDA's feedback, the predicate analysis, and clinical results. A submitted application with constructive FDA feedback supports a higher probability of success than a plan that has not yet been discussed with the agency.

The appraiser does not need to predict FDA's decision. The task is to weight realistic outcomes, including a delay or a request for more data, and to tie the weights to the company's evidence and to the price investors recently paid.

Reimbursement: The Second Gate in a Healthcare Startup 409A Valuation

Many medtech forecasts assume sales begin soon after clearance. In practice, hospitals and physicians adopt a new device more slowly if no one pays for its use. Reimbursement has three parts, and the appraiser checks where the company stands on each:

• Coverage. Whether Medicare and commercial insurers will pay for the procedure or test at all. Medicare coverage can come from a national or local coverage determination; commercial payers make their own decisions. CMS's Transitional Coverage for Emerging Technologies (TCET) pathway, finalized in 2024, can speed Medicare coverage for some Breakthrough-designated devices.
• Coding. Whether an existing billing code describes the procedure. A new CPT Category III code is a temporary tracking code and is often not paid on a set fee schedule; obtaining a Category I code generally requires evidence of widespread clinical use.
• Payment. Whether the amount paid covers the device and gives the provider a reason to use it. Temporary add-on payments for new technology can help hospitals during the first years.

A forecast that assumes full reimbursement from launch should be adjusted, either through a slower revenue ramp or a scenario in which coverage takes years. The same logic applies to diagnostics, where a test may be performed often but paid only a fraction of the time. Value follows paid tests, not tests run.

Valuing Medtech Revenue: Comparables, Margins and the Sales Ramp

Once a device or diagnostics company is selling, the market approach becomes central. Appraisers compare the company with listed medical device and diagnostics companies, with acquisitions of private medtech companies as a cross-check. Several points shape how those comparables are used in a 409A valuation for a medtech company:

• Gross margin. Devices with high gross margins and recurring disposables support higher revenue multiples than capital equipment sold once with thin margins.
• Razor-and-blade models. A system placed in a hospital that drives repeat purchases of single-use components behaves more like recurring revenue. Appraisers separate one-time capital sales from recurring consumables before choosing a multiple.
• Size and concentration. Listed device companies sell many products across many indications; a startup may depend on one product. A multiple below the peer median is usually selected unless growth or margins justify more.
• Acquisition prices need care. Large strategic buyers often pay for synergies, such as putting a device into an existing global sales force, that a minority holder of common stock would not receive.
• Product liability and recalls. A recall, an FDA warning letter or significant litigation is weighed as a specific risk, not left to a generic discount rate.

Hardware economics also matter: inventory, contract manufacturing and the cost of a field sales team affect cash burn and runway. Our guide to 409A valuations for hardware startups covers those issues in more depth.

How is a digital health startup valued for a 409A?

A digital health startup is usually valued much like a software company, through its latest financing and revenue multiples drawn from health-IT and software peers. The appraiser then adjusts for healthcare-specific factors: long enterprise sales cycles with hospitals and payers, customer concentration, and whether any software functions are regulated by FDA as medical devices.

Three questions tend to drive a digital health 409A valuation:

• Is any of the software a medical device? Software that diagnoses or treats a condition can be regulated as software as a medical device, while many administrative, wellness and some clinical decision support tools are not. Regulated software brings device-style clearance risk into the valuation.
• Who pays, and how? Subscription revenue from health systems is valued differently from revenue that depends on billing insurers per patient, which brings reimbursement risk back in.
• How recurring is the revenue? Multi-year enterprise contracts with high renewal rates support software-style multiples. Pilots and one-time implementation fees do not, until they convert.

Pre-revenue health-IT companies are generally valued through their latest round, using an option pricing model solved back to the price investors paid through a backsolve.

A Worked Example: Common Stock at a Pre-Clearance Device Company

Consider an illustrative medical device company with these facts on its valuation date:

• A novel Class II device with a De Novo request in preparation and no material revenue yet
• 10.0M common shares, including options, treated as outstanding common for simplicity
• 4.0M Seed preferred shares issued at $1.25 and 6.0M Series A preferred shares issued recently at $3.00, both with a 1x non-participating liquidation preference, ranking equally
• Liquidation preferences of $23.0M in total ($5.0M Seed and $18.0M Series A)
• An exit or liquidity event assumed three years out, after the FDA decision and early reimbursement work, discounted at 25%, since the scenario probabilities already capture much of the regulatory risk

The appraiser sets three scenarios and calibrates the probabilities so the model values the Series A shares at about the $3.00 investors just paid:

The probability-weighted value of common at exit is $5.00 per share (35% × $12.50 plus 40% × $1.57). The remaining steps:

The calibration check matters. The same scenarios value a Series A share at $2.99, close to the $3.00 price paid, which supports the probabilities used. The present value of total equity across the scenarios is about $54.0M, below the $60.0M post-money figure, because preferred stock's downside protection is worth more than a share of common. The 30% discount for lack of marketability reflects the three-year horizon; our comparison of DLOM models explains how that figure is estimated.

Notice where common's value comes from: about 87% of its expected value at exit comes from the strong-adoption scenario. If the evidence supported a 25% chance of that outcome instead of 35%, with the rest shifted to the failed submission, common's value would fall by about 25% before any recalibration. That sensitivity is why the support for each probability, such as FDA feedback and reimbursement progress, belongs in the report. For why common trails the preferred price in general, see our explainer on the 409A price vs the preferred price.

Does FDA clearance require a new 409A valuation?

Usually, yes. An FDA clearance, De Novo grant or approval resolves much of the uncertainty the previous 409A had to estimate, so it is typically a material event. Options granted afterward should be priced off a valuation that reflects the decision. The same applies in reverse to a rejection, a major request for new data or a clinical hold.

The reason is the regulation itself. Treasury Regulations Section 1.409A-1(b)(5)(iv)(B)(2)(i) gives a presumption of reasonableness to a valuation by a qualified independent appraiser as of a date no more than 12 months before the grant, but a valuation is not reasonable if it fails to reflect information available after its date that may materially affect value. Our guide to material events and the 409A covers that test in detail. Events that commonly qualify for a medtech or healthcare company include:

• An FDA clearance, De Novo grant, approval or rejection, or a significant additional-information request
• Pivotal or other clinical results, positive or negative
• A Medicare coverage decision, a new payment code or a major commercial payer contract
• A recall, a warning letter or a significant quality issue
• A new financing, a strategic partnership, or an acquisition offer or letter of intent

Grant timing around a decision deserves particular care. Options granted in the weeks after a clearance, on a valuation that assumed meaningful regulatory risk, may be priced below fair market value. If options are granted below fair market value and no exemption applies, they can be treated as deferred compensation under Section 409A. If they then fail to comply, the holder may owe income tax on vested amounts, an additional 20% federal tax and premium interest, and some states, such as California, add their own tax. See our 409A safe harbor guide for the full rules.

What a Medtech Company Should Prepare for Its 409A

A healthcare startup can usually get a 409A valuation within a few days to about two weeks, depending on the provider and how quickly it supplies documents. Our guide to getting a fast 409A valuation explains how to shorten the timeline. The documents that matter most for a medtech company are:

• The cap table, charter, and all preferred stock, SAFE and warrant documents
• Financial statements and the current cash runway
• The regulatory plan: device classification, chosen pathway, predicate analysis, pre-submission feedback and submission status
• Clinical study protocols and any results to date
• The reimbursement plan: target codes, coverage strategy and payer conversations
• Distribution, licensing, co-development and supply agreements, including any exclusivity or rights on a sale
• Sales, unit volume and gross margin history for any products already on the market

The Bottom Line on 409A Valuations for Healthcare and Medtech Companies

A 409A valuation for a medtech company follows the same rules as any other, but the evidence is organized around two gates: FDA and reimbursement. Pre-clearance device companies are typically valued through their latest financing and scenarios calibrated to it. Commercial-stage device and diagnostics companies add revenue multiples from medtech peers, adjusted for margins and concentration. Health-IT companies are often valued like software, unless their software is itself a regulated device.

For founders and CFOs, the practical points are these. Expect the appraiser to ask for regulatory and reimbursement evidence, not just a forecast. Expect much of common's value to come from the success scenario. Expect a clearance, a rejection or a coverage decision to call for a fresh valuation. And keep the regulatory file current, so a post-clearance hiring wave is not held up by an out-of-date 409A valuation for your medtech company.

The figures in this article are illustrative, based on simplified inputs (options are treated as outstanding common, a single exit date and discount rate are used across scenarios, and one discount for lack of marketability is applied to the weighted result), and are not a valuation of any company. Regulatory and reimbursement descriptions are general summaries and may change. This article is general information about Section 409A and valuation practice, not legal, tax, regulatory or accounting advice. Whether a valuation qualifies for a presumption of reasonableness under Treasury Regulations Section 1.409A-1(b)(5)(iv)(B) depends on the specific facts; consult your own counsel and tax advisor.